{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:59:55Z","timestamp":1791500395646,"version":"4.3.4"},"reference-count":120,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":2068,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:p>The hallmark of CML (chronic myeloid leukaemia) is the BCR (breakpoint cluster region)\u2013ABL fusion gene. CML evolves through three phases, based on both clinical and pathological features: a chronic phase, an accelerated phase and blast crisis. TKI (tyrosine kinase inhibitors) are the treatment modality for patients with chronic phase CML. The therapeutic potential of the TKI imatinib is affected by BCR\u2013ABL dependent an independent mechanisms. Development of MDR (multidrug resistance) contributes to the overall clinical resistance. MDR involves overexpression of ABC -transporters (ATP-binding-cassette transporter) among other features. MDR studies include the analysis of cancer cell lines selected for resistance. CML blast crisis is accompanied by increased resistance to apoptosis. This work reviews the role played by the influx transporter OCT1 (organic cation transporter 1), by efflux ABC transporters, molecules involved in the modulation of apoptosis (p53, Bcl-2 family, CD95, IAPs (inhibitors of apoptosis protein)], Hh and Wnt\/\u03b2-catenin pathways, cytoskeleton abnormalities and other features described in leukaemic cells of clinical samples and CML cell lines. An MDR cell line, Lucena-1, generated from K562 by stepwise exposure to vincristine, was used as our model and some potential anticancer drugs effective against the MDR cell line and patients\u2019 samples are presented.<\/jats:p>","DOI":"10.1042\/bsr20130067","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T08:17:38Z","timestamp":1380269858000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR\u2013CML cell lines?"],"prefix":"10.1042","volume":"33","author":[{"given":"Vivian\u00a0M.","family":"Rumjanek","sequence":"first","affiliation":[{"name":"Instituto de Bioqu\u00edmica M\u00e9dica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael\u00a0S.","family":"Vidal","sequence":"additional","affiliation":[{"name":"Instituto de Bioqu\u00edmica M\u00e9dica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel\u00a0C.","family":"Maia","sequence":"additional","affiliation":[{"name":"Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2013,11,25]]},"reference":[{"key":"2021111618120637700_B1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"American J. Hematol."},{"key":"2021111618120637700_B2","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"13","author":"Faderl","year":"1999","journal-title":"Oncology (Williston Park, NY)"},{"key":"2021111618120637700_B3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2021111618120637700_B4","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111618120637700_B5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"New Engl. J. Med."},{"key":"2021111618120637700_B6","first-page":"384","article-title":"The Biology of CML blast crisis. Hematology\/the Education Program of the American Society of Hematology. American Society of Hematology","author":"Radich","year":"2007","journal-title":"Education Program"},{"key":"2021111618120637700_B7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"2021111618120637700_B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","article-title":"Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review","volume":"87","author":"Vaidya","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"2021111618120637700_B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Semin. Oncol."},{"key":"2021111618120637700_B10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"2021111618120637700_B11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"New Engl. J. Med."},{"key":"2021111618120637700_B12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"2021111618120637700_B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-4598-5-55","article-title":"Pathway-specific differences between tumor cell lines and normal and tumor tissue cells","volume":"5","author":"Ertel","year":"2006","journal-title":"Mol. Cancer"},{"key":"2021111618120637700_B14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"2021111618120637700_B15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.2910230202","article-title":"K562\u2013a human erythroleukemic cell line. International journal of cancer","volume":"23","author":"Andersson","year":"1979","journal-title":"J. Int. Cancer"},{"key":"2021111618120637700_B16","first-page":"822","article-title":"Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics","volume":"15","author":"Seigneurin","year":"1987","journal-title":"Exp. Hematol."},{"key":"2021111618120637700_B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Kubonishi","year":"1983","journal-title":"Int. J. Cell Cloning"},{"key":"2021111618120637700_B18","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0145-2126(85)90314-5","article-title":"A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis","volume":"9","author":"Ohkubo","year":"1985","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B19","first-page":"751","article-title":"Establishment and properties of vincristine-resistant human myelogenous leukemia K562","volume":"74","author":"Tsuruo","year":"1983","journal-title":"Gann"},{"key":"2021111618120637700_B20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in\u00a0vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"2021111618120637700_B21","first-page":"671702","article-title":"The interface between BCR\u2013ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk. Res. Treat."},{"key":"2021111618120637700_B22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Therap."},{"key":"2021111618120637700_B23","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021111618120637700_B24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-5956-10-23","article-title":"A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line","volume":"10","author":"Corr\u00eaa","year":"2012","journal-title":"Proteome Sci."},{"key":"2021111618120637700_B25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Hirayama","year":"2008","journal-title":"Pharm. Res."},{"key":"2021111618120637700_B26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-11-1590","article-title":"Molecular pathways: regulation and therapeutic implications of multidrug resistance","volume":"18","author":"Chen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2021111618120637700_B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111618120637700_B28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.1990.tb02533.x","article-title":"Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis","volume":"74","author":"Kuwazuru","year":"1990","journal-title":"Br. J. Haematol."},{"key":"2021111618120637700_B29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jnci\/82.13.1133","article-title":"Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine","volume":"82","author":"Herweijer","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111618120637700_B30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"2021111618120637700_B31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E","article-title":"Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance","volume":"86","author":"Giles","year":"1999","journal-title":"Cancer"},{"key":"2021111618120637700_B32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B"},{"key":"2021111618120637700_B33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","article-title":"Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice","volume":"31","author":"Vasconcelos","year":"2007","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"2021111618120637700_B35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Mosc)"},{"key":"2021111618120637700_B36","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1172\/JCI116447","article-title":"Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents","volume":"91","author":"Hait","year":"1993","journal-title":"J. Clin. Invest."},{"key":"2021111618120637700_B37","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol. Rep."},{"key":"2021111618120637700_B38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001813-200103000-00010","article-title":"Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines","volume":"12","author":"Grandjean","year":"2001","journal-title":"Anticancer Drugs"},{"key":"2021111618120637700_B39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11010-013-1761-0","article-title":"Characterization of a multidrug resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms","volume":"383","author":"Daflon-Yunes","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"2021111618120637700_B40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1015548706673","article-title":"Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia","volume":"19","author":"Lopes","year":"2002","journal-title":"Clin. Exp. Metastasis"},{"key":"2021111618120637700_B41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","article-title":"Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"Anais da Academia Brasileira de Ci\u00eancias"},{"key":"2021111618120637700_B42","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"2021111618120637700_B43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"2021111618120637700_B44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","article-title":"Complex interaction of BCRP\/ABCG2 and imatinib in BCR\u2013ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression","volume":"108","author":"Nakanishi","year":"2006","journal-title":"Blood"},{"key":"2021111618120637700_B45","first-page":"1967","article-title":"Overcoming of vincristine resistance in P388 leukemia in\u00a0vivo and in\u00a0vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Res."},{"key":"2021111618120637700_B46","first-page":"1050","article-title":"Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein","volume":"5","author":"Cumber","year":"1991","journal-title":"Leukemia"},{"key":"2021111618120637700_B47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1874467210801020093","article-title":"Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies","volume":"1","author":"Wu","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"2021111618120637700_B48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425255.2011.562892","article-title":"Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?","volume":"7","author":"Br\u00f3zik","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2021111618120637700_B49","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","article-title":"Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase","volume":"100","author":"List","year":"2002","journal-title":"Blood"},{"key":"2021111618120637700_B50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2257.1997.tb00011.x","article-title":"Interaction of cyclosporin A and etoposide. Clinical and in\u00a0vitro assessment in blast phase of chronic myeloid leukaemia","volume":"19","author":"Maia","year":"1997","journal-title":"Clin. Lab. Haematol."},{"key":"2021111618120637700_B51","first-page":"419","article-title":"Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide","volume":"16","author":"Maia","year":"1997","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2021111618120637700_B52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"2021111618120637700_B53","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"2021111618120637700_B54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1634\/theoncologist.5-5-405","article-title":"Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis","volume":"5","author":"Di Bacco","year":"2000","journal-title":"Oncologist"},{"key":"2021111618120637700_B55","first-page":"582","article-title":"The involvement of \u2018tumor suppressor\u2019 p53\u00a0in normal and chronic myelogenous leukemia hemopoiesis","volume":"54","author":"Bi","year":"1994","journal-title":"Cancer Res."},{"key":"2021111618120637700_B56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/cc.6.5.3900","article-title":"Apaf1\u00a0in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis","volume":"6","author":"Ashur-Fabian","year":"2007","journal-title":"Cell Cycle"},{"key":"2021111618120637700_B57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cyto.b.20514","article-title":"P53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome","volume":"78","author":"Cavalcanti","year":"2010","journal-title":"Cytometry B"},{"key":"2021111618120637700_B58","first-page":"839","article-title":"p53\u00a0in chronic myeloid leukemia cell lines","volume":"6","author":"Bi","year":"1992","journal-title":"Leukemia"},{"key":"2021111618120637700_B59","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"2021111618120637700_B60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","author":"Amarante-Mendes","year":"1998","journal-title":"Oncogene"},{"key":"2021111618120637700_B61","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","article-title":"Bcr\/Abl activates transcription of the Bcl-X gene through STAT5","volume":"96","author":"Gesbert","year":"2000","journal-title":"Blood"},{"key":"2021111618120637700_B62","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/1097-0142(20010601)91:11<1964::AID-CNCR1221>3.0.CO;2-B","article-title":"Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance","volume":"91","author":"Ravandi","year":"2001","journal-title":"Cancer"},{"key":"2021111618120637700_B63","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"2021111618120637700_B64","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/MCB.24.23.10289-10299.2004","article-title":"Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release","volume":"24","author":"Deming","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021111618120637700_B65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bcmd.2010.07.011","article-title":"BAX\/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia","volume":"45","author":"Gonzalez","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"2021111618120637700_B66","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res."},{"key":"2021111618120637700_B67","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr\u2013Abl-expressing hematopoietic progenitors","volume":"24","author":"Kuribara","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021111618120637700_B68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1025586225941","article-title":"Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line","volume":"252","author":"Wagner-Souza","year":"2003","journal-title":"Mol. Cell. Biochem."},{"key":"2021111618120637700_B69","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood.V92.3.981","article-title":"Fas-mediated modulation of Bcr\/Abl in chronic myelogenous leukemia results in differential effects on apoptosis","volume":"92","author":"Selleri","year":"1998","journal-title":"Blood"},{"key":"2021111618120637700_B70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10428190009089429","article-title":"The role of FAS-mediated apoptosis in chronic myelogenous leukemia","volume":"37","author":"Selleri","year":"2000","journal-title":"Leuk. Lymph."},{"key":"2021111618120637700_B71","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.leukres.2005.08.006","article-title":"A Fas agonist induces high levels of apoptosis in haematological malignancies","volume":"30","author":"Greaney","year":"2006","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B72","first-page":"25","article-title":"Does CD95 have tumor promoting activities?","volume":"1755","author":"Peter","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111618120637700_B73","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/sj.embor.7400280","article-title":"Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds","volume":"5","author":"Legembre","year":"2004","journal-title":"EMBO Rep."},{"key":"2021111618120637700_B74","doi-asserted-by":"crossref","first-page":"22625","DOI":"10.1074\/jbc.270.38.22625","article-title":"Regulation of the Fas apoptotic cell death pathway by Abl","volume":"270","author":"McGahon","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021111618120637700_B75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00282-997-0075-7","article-title":"Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing","volume":"39","author":"Munker","year":"1997","journal-title":"Hematol. Cell Ther."},{"key":"2021111618120637700_B76","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.cdd.4400303","article-title":"Bcr\u2013abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines","volume":"4","author":"Belloc","year":"1997","journal-title":"Cell Death Differ."},{"key":"2021111618120637700_B77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nature Rev. Drug Disc."},{"key":"2021111618120637700_B78","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature"},{"key":"2021111618120637700_B79","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","article-title":"Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients","volume":"46","author":"Hern\u00e1ndez-Boluda","year":"2005","journal-title":"Leuk. Lymph."},{"key":"2021111618120637700_B80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","article-title":"Survivin expression in chronic myeloid leukemia","volume":"225","author":"Conte","year":"2005","journal-title":"Cancer Lett."},{"key":"2021111618120637700_B81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009060314","article-title":"A role for P-glycoprotein in regulating cell death","volume":"38","author":"Johnstone","year":"2000","journal-title":"Leuk. Lymph."},{"key":"2021111618120637700_B82","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","article-title":"High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia","volume":"10","author":"Tamm","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2021111618120637700_B83","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B84","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3109\/10428194.2011.572323","article-title":"Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein","volume":"52","author":"Hu","year":"2011","journal-title":"Leuk. Lymph."},{"key":"2021111618120637700_B85","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int. J. Oncol."},{"key":"2021111618120637700_B86","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.leukres.2012.08.014","article-title":"Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells","volume":"36","author":"Bernardo","year":"2012","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B87","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Leuk. Lymph."},{"key":"2021111618120637700_B88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jcp.22140","article-title":"Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells","volume":"224","author":"Ciarcia","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"2021111618120637700_B89","first-page":"F89","article-title":"Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis","volume":"28","author":"Sulov\u00e1","year":"2009","journal-title":"Gen. Physiol. Biophys."},{"key":"2021111618120637700_B90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152013804487380","article-title":"New insight into p-glycoprotein as a drug target","volume":"13","author":"Breier","year":"2013","journal-title":"Anti-cancer Agents Med. Chem."},{"key":"2021111618120637700_B91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11010-006-9154-2","article-title":"Effect of extracellular ATP on the human leukaemic cell line K562 and its multidrug counterpart","volume":"289","author":"Bernardo","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"2021111618120637700_B92","first-page":"436","article-title":"Chronic myeloid leukemia stem cells. Hematology\/the Education Program of the American Society of Hematology. American Society of Hematology","author":"Jamieson","year":"2008","journal-title":"Education Program"},{"key":"2021111618120637700_B93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2210-10-12","article-title":"Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells","volume":"10","author":"Tang","year":"2010","journal-title":"BMC Pharmacol."},{"key":"2021111618120637700_B94","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-10-0510","article-title":"c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells","volume":"9","author":"Porro","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"2021111618120637700_B95","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1349-7006.2010.01584.x","article-title":"Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells","volume":"101","author":"Naka","year":"2010","journal-title":"Cancer Sci."},{"key":"2021111618120637700_B96","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.leu.2404657","article-title":"Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression","volume":"21","author":"Sengupta","year":"2007","journal-title":"Leukemia"},{"key":"2021111618120637700_B97","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1038\/onc.2010.375","article-title":"Hedgehog signaling maintains chemoresistance in myeloid leukemic cells","volume":"29","author":"Queiroz","year":"2010","journal-title":"Oncogene"},{"key":"2021111618120637700_B98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2407-12-303","article-title":"Wnt\/\u03b2-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia","volume":"12","author":"Corr\u00eaa","year":"2012","journal-title":"BMC Cancer"},{"key":"2021111618120637700_B99","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.leukres.2009.11.004","article-title":"Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines","volume":"34","author":"Marques","year":"2010","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.13025FP","article-title":"Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties","volume":"122","author":"Xin","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"2021111618120637700_B101","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hep.23692","article-title":"Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway","volume":"52","author":"Wang","year":"2010","journal-title":"Hepatology"},{"key":"2021111618120637700_B102","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2005.02.018","article-title":"Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues","volume":"121","author":"Hochedlinger","year":"2005","journal-title":"Cell"},{"key":"2021111618120637700_B103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cellsig.2009.12.012","article-title":"The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS\/Slp-76\/Nck1 adaptor protein pathway","volume":"22","author":"Preisinger","year":"2010","journal-title":"Cell. Signal."},{"key":"2021111618120637700_B104","first-page":"871","article-title":"Golgi complex is brefeldin A resistant in multidrug resistant cells","volume":"12","author":"Erokhina","year":"1999","journal-title":"Membr. Cell Biol."},{"key":"2021111618120637700_B105","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.cellbi.2007.05.010","article-title":"Sensitivity to microcystins: a comparative study in human cell lines with and without multidrug resistance phenotype","volume":"31","author":"De Souza Votto","year":"2007","journal-title":"Cell Biol. Int."},{"key":"2021111618120637700_B106","doi-asserted-by":"crossref","first-page":"e44312","DOI":"10.1371\/journal.pone.0044312","article-title":"Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins","volume":"7","author":"Ferreira","year":"2012","journal-title":"PloS ONE"},{"key":"2021111618120637700_B107","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10637-007-9064-5","article-title":"Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile","volume":"25","author":"Vasconcelos","year":"2007","journal-title":"Invest. New Drugs"},{"key":"2021111618120637700_B108","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Maia","year":"2011","journal-title":"Invest. New Drugs"},{"key":"2021111618120637700_B109","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1751-1097.1999.tb03348.x","article-title":"Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein","volume":"69","author":"Trindade","year":"1999","journal-title":"Photochem. Photobiol."},{"key":"2021111618120637700_B110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1042\/BSR20100115","article-title":"Anti-MDR and antitumoral action of acetylsalicylic acid on leukemic cells","volume":"31","author":"Dias","year":"2011","journal-title":"Biosci. Rep."},{"key":"2021111618120637700_B111","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3835(02)00593-1","article-title":"Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines","volume":"190","author":"Fernandes","year":"2003","journal-title":"Cancer Lett."},{"key":"2021111618120637700_B112","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1016\/j.bmc.2007.07.020","article-title":"Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines","volume":"15","author":"da Rocha","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"2021111618120637700_B113","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10565-007-9003-4","article-title":"Vanadate-induced cell death is dissociated from H2O2 generation","volume":"23","author":"Capella","year":"2007","journal-title":"Cell Biol. Toxicol."},{"key":"2021111618120637700_B114","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-005-1014-3","article-title":"Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy","volume":"56","author":"Kirszberg","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021111618120637700_B115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0145-2126(02)00094-2","article-title":"CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype","volume":"27","author":"Silva","year":"2003","journal-title":"Leuk. Res."},{"key":"2021111618120637700_B116","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejmech.2008.01.027","article-title":"(+\/\u2212)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives: cytotoxic effect on human leukemia cell lines","volume":"44","author":"Netto","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"2021111618120637700_B117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10637-009-9231-y","article-title":"Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells","volume":"28","author":"Salustiano","year":"2010","journal-title":"Invest. New Drugs"},{"key":"2021111618120637700_B118","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bmc.2009.12.073","article-title":"New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells","volume":"18","author":"Netto","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"2021111618120637700_B119","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkr988","article-title":"KEGG for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Kanehisa","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2021111618120637700_B120","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/sj.onc.1206950","article-title":"Transcriptional regulation of ABC drug transporters","volume":"22","author":"Scotto","year":"2003","journal-title":"Oncogene"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20130067\/475223\/bsr033e081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20130067\/475223\/bsr033e081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:22:50Z","timestamp":1716009770000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/33\/6\/e00081\/55969\/Multidrug-resistance-in-chronic-myeloid-leukaemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,25]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20130067","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,25]]},"article-number":"e00081"}}